Sign in
Taking people in United StatesPhase 1

Tests inhaled KB407 for cystic fibrosis in adults

Tests safety of an inhaled gene therapy at rising doses in adults with cystic fibrosis.

Key facts

Who runs it
Krystal Biotech, Inc.
Where
Boise, Gainesville, Hawthorne, New York, Northfield, and Winston-Salem, United StatesSee the 6 sites
Trial code
Registry title
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
Status
Recruiting
Phase
Phase 1
People taking part
20 people, planned
Started
30 Jun 2023
Expected to end
Mar 2027
Type of study
Interventional, 4 groups
Treatments tested
  • KB407 (Nebulization)
Record updated
7 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cystic fibrosis who are clinically stable and have moderately reduced lung function. It tests the safety of inhaled KB407.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Confirmed cystic fibrosis, clinically stable, with FEV1 (lung function) between 40% and 90% of the predicted normal value, and resting oxygen saturation of 92% or more on room air.
Earlier treatment
No new or changed long-term cystic fibrosis treatment (for example a CFTR modulator, hypertonic saline or an inhaled antibiotic) within 28 days before the first dose. No other investigational drug within 30 days or 5 half-lives, whichever is longer.
Biomarker or test result
Sweat chloride above 60 mmol/L in the past, or two copies of a disease-causing mutation in the CFTR gene.

Main reasons for not taking part

  • History of solid organ transplant, or on a transplant list
  • Pregnant or nursing women
  • Hospitalization, lung infection or cystic fibrosis flare-up within 14 days before the first dose
  • Active oral herpes infection within 30 days before the first dose
  • Known allergy to inhaled glycerol

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • The subject must have read, understood, and signed an Institutional Review Board/Ethics Committee (IRB/IEC) approved Informed Consent Form and must be able to and willing to follow study procedures and instructions
  • Subjects aged 18 years or older at the time of Informed Consent
  • A confirmed diagnosis of CF as defined by clinical signs and symptoms of CF and at least one of the following:; A historical sweat chloride value >60 mmol/L; Two copies of a disease causing mutation in the CFTR gene
  • Clinically stable in the opinion of the Investigator
  • Percent predicted FEV1 ≥40% and ≤90% of the predicted normal for age, gender, and height at Screening
  • Resting oxygen saturation ≥92% on room air at Screening

Who cannot take part

  • Initiation of any new chronic therapy (eg, CFTR modulator, hypertonic saline, inhaled antibiotic) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to the first dose
  • Hospitalization, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness 14 days prior to the first dose that, in the opinion of the Investigator, may confound study results
  • Treatment for Mycobacterium abscessus within 3 months prior to the first dose or more than two pulmonary exacerbations with a history of Burkholderia cenocepacia infection within 6 months prior to the first dose
  • Participation in another clinical study or treatment with an investigational agent 30 days or 5 half-lives, whichever is longer, prior to the first dose
  • An active oral herpes infection 30 days prior to the first dose
  • Cohort 4 participants only: Subjects who are ineligible for, do not tolerate, or do not benefit from modulator therapy
  • History of or listed for solid organ transplantation
  • Any condition (including a history or current evidence of substance abuse or dependence, uncontrolled asthma, or is considered to be immunocompromised) that, in the opinion of the Investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of KB407
  • Subject has a known hypersensitivity to inhaled glycerol
  • Women who are pregnant or nursing
  • Subject who is unwilling to comply with contraception requirements per protocol
  • Clinically significant abnormalities of hematology or chemistry testing at Screening that the Investigator believes may interfere with the assessment of safety and/or efficacy of the study treatment
  • Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the Investigator
  • Bronchoscopy participants only: Unable to tolerate bronchoscopy procedure and airway sampling, in the opinion of the Investigator

Where in United States

  • St. Lukes CF Center of IdahoBoise, United StatesContact: Dixie DurhamTaking people
  • University of Florida - GainesvilleGainesville, United StatesContact: Alexa SmithTaking people
  • New York Medical College/ Boston Children's Health PhysiciansHawthorne, United StatesContact: Armando Ramirez, CRCTaking people
  • Northwell Health PhysiciansNew York, United StatesContact: Teresa DemarcoTaking people
  • The Cystic Fibrosis InstituteNorthfield, United StatesContact: Karolina RoszkoTaking people
  • Atrium Health Wake Forest Baptist Medical CenterWinston-Salem, United StatesContact: Christian SmithTaking people

About the trial

What the trial wants to find out

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

The 4 groups in the trial

  • Cohort 1 (open label)Treatment being tested

    A single administration of KB407

    Treatment: KB407 (Nebulization)

  • Cohort 2 (open label)Treatment being tested

    Two administrations of KB407

    Treatment: KB407 (Nebulization)

  • Cohort 3 (open label)Treatment being tested

    Four administrations of KB407

    Treatment: KB407 (Nebulization)

  • Cohort 4 (open label)Treatment being tested

    Four consecutive administrations of KB407 followed by weekly administration for up to 6 months

    Treatment: KB407 (Nebulization)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis
Plain-language title
Tests inhaled KB407 for cystic fibrosis in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
7 May 2026